To evaluate the safety and IOP-lowering effects of WB007 in adults with primary open-angle
glaucoma or ocular hypertension in both eyes. This is a 2-part study. Part 1 will look at up
to 3 formulations of WB007 ophthalmic solution following a single dose in one eye. Part 2
will look at up to 2 formulations of WB007 (to be selected based on results from Part 1) in
both eyes compared with timolol 0.5% for 14 days.